Valuation: Sunflower Pharmaceutical Group Co., Ltd.

Market Cap 689.7Cr 103.53Cr 94Cr 87Cr 78Cr 147.93Cr 9.76TCr 152.9Cr 1.04TCr 414.12Cr 5.22TCr 388.41Cr 380.22Cr 17TCr P/E 2024
24.4x
P/E 2025 -33.6x
Enterprise Value 440.49Cr 66Cr 60Cr 56Cr 50Cr 94Cr 6.23TCr 98Cr 667.15Cr 264.48Cr 3.33TCr 248.06Cr 242.83Cr 11TCr EV / Sales 2024
2.87x
EV / Sales 2025 2.65x
Free-Float
42.02%
Yield 2024
2.44%
Yield 2025 1.35%
30/10 Sunflower Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
14/10 Sunflower Pharmaceutical Gets Board Nod to Cancel Wholly-Owned Subsidiary MT
13/10 Harbin Hongye Pharmaceutical Co., Ltd. announced that it has received CNY 4 million in funding from Sunflower Pharmaceutical Group Co., Ltd. CI
13/10 Heilongjiang Dongxu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 5 million in funding from Sunflower Pharmaceutical Group Co., Ltd. CI
23/09 Sunflower Pharmaceutical Group Co., Ltd. agreed to acquire Heilongjiang Dongxu Pharmaceutical Co., Ltd. from Yang Dongxu and Yang Huaizhou for CNY 0.78 million. CI
28/08 Sunflower Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
28/07 Sunflower Pharmaceutical Withdraws Investment in Fund MT
28/07 Sunflower Pharmaceutical Commits 10 Million Yuan to Set Up Subsidiary in Sichuan, China MT
28/07 Sunflower Pharmaceutical Offloads Beijing Pharmastar Stake for 34 Million Yuan MT
27/07 Guangzhou Baiyunshan Hejigong Pharmaceutical Co., Ltd. agreed to acquire 10.39% stake in Beijing Pharmstar Pharmaceutical Technology from Sunflower Pharmaceutical Group Co., Ltd. for CNY 34.3 million. CI
26/05 Sunflower Pharmaceutical Group Co.,Ltd Approves Cash Dividend for 2025 CI
06/05 Sunflower Pharmaceutical Products Selected for Bulk Chinese Medicine Procurement MT
29/04 Sunflower Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
1 day-0.76%
1 week-2.15%
Current month-0.34%
1 month+4.24%
3 months-13.35%
6 months-13.23%
Current year-20.04%
1 week 11.66
Extreme 11.66
12.14
1 month 10.95
Extreme 10.95
12.33
Current year 10.95
Extreme 10.95
15.19
1 year 10.95
Extreme 10.95
15.42
3 years 10.95
Extreme 10.95
30.79
5 years 10.95
Extreme 10.95
31.48
10 years 10.95
Extreme 10.95
31.48
Manager TitleAgeSince
Chief Executive Officer 58 09/02/2026
Director of Finance/CFO 49 06/12/2021
Corporate Officer/Principal 56 20/03/2025
Director TitleAgeSince
Director/Board Member 66 26/03/2014
Director/Board Member 64 26/09/2017
Director/Board Member 44 26/09/2017
Date Insider Type Main position Quantity % Market Cap. Importance
17/07/24 Buy 500 0.0001%
22/01/20 Sell

Director

2,46,300 0.0462%
01/01/20 Sell 21,300 0.0040%
Change 5-day change 1-year change 3-year change Capi.($)
-0.76%-2.15%-20.79%-52.34% 103.32Cr
+1.26%+6.61%+41.12%+135.59% 1,28600Cr
+0.79%+3.45%+46.35%+93.56% 69TCr
+0.20%+1.28%+27.01%+112.80% 52TCr
-0.44%+3.69%+39.60%+69.51% 39TCr
+0.55%+0.70%+59.00%+44.20% 36TCr
-0.12%+0.74%+26.78%+58.43% 30TCr
+0.37%+0.37%+3.62%+36.44% 29TCr
-0.30%+1.14%+38.59%+74.61% 25TCr
+0.08%+0.71%+34.25%+124.32% 21TCr
Average +0.16%+1.69%+29.55%+69.71% 43TCr
Weighted average by Cap. +0.54%+3.25%+37.62%+96.19%

Financials

2024 2025
Net sales 337.7Cr 51Cr 46Cr 43Cr 38Cr 72Cr 4.78TCr 75Cr 511.48Cr 202.77Cr 2.56TCr 190.18Cr 186.17Cr 8.09TCr 231.8Cr 35Cr 32Cr 29Cr 26Cr 50Cr 3.28TCr 51Cr 351.07Cr 139.18Cr 1.75TCr 130.54Cr 127.79Cr 5.56TCr
Net income 49Cr 7.39Cr 6.71Cr 6.2Cr 5.6Cr 11Cr 696.03Cr 11Cr 75Cr 30Cr 372.45Cr 28Cr 27Cr 1.18TCr -26Cr -3.87Cr -3.52Cr -3.25Cr -2.93Cr -5.53Cr -364.71Cr -5.72Cr -39Cr -15Cr -195.16Cr -15Cr -14Cr -618Cr
Net Debt -228.95Cr -34Cr -31Cr -29Cr -26Cr -49Cr -3.24TCr -51Cr -346.76Cr -137.47Cr -1.73TCr -128.93Cr -126.22Cr -5.49TCr -249.22Cr -37Cr -34Cr -31Cr -28Cr -53Cr -3.53TCr -55Cr -377.46Cr -149.64Cr -1.89TCr -140.35Cr -137.39Cr -5.97TCr
Projected Income Statement - Annual - Sunflower Pharmaceutical Group Co., Ltd.
Logo Sunflower Pharmaceutical Group Co., Ltd.
Sunflower Pharmaceutical Group Co Ltd is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company operates its businesses through three segments. The Headquarters Segment is responsible for investment management. The Pharmaceutical segment is mainly responsible for pharmaceutical production and sales. Other segment is mainly responsible for the production of packaging materials and the cultivation and research of Chinese herbal medicines. The Company’s main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in the domestic market.
Employees
5,025
Date Price Change Volume
13/26/13 CN¥11.81 -0.76% 54,06,133
12/26/12 CN¥11.90 +0.68% 64,22,200
11/26/11 CN¥11.82 -0.92% 36,83,500
10/26/10 CN¥11.93 -0.83% 39,96,000
09/26/09 CN¥12.03 -0.33% 42,56,300

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Sunflower Pharmaceutical Group Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 002737 Stock